PuSH - Publication Server of Helmholtz Zentrum München

Vesting, A.J.* ; Jais, A. ; Klemm, P.* ; Steuernagel, L.* ; Wienand, P.* ; Fog-Tonnesen, M.* ; Hvid, H.* ; Schumacher, A.L.* ; Kukat, C.* ; Nolte, H.* ; Georgomanolis, T.* ; Altmüller, J.* ; Pasparakis, M.* ; Schmidt, A.* ; Krüger, M.* ; Supprian, M.S.* ; Waisman, A.* ; Straub, B.K.* ; Raschzok, N.* ; Bernier, M.* ; Birkenfeld, A.L. ; Hövelmeyer, N.* ; Brüning, J.C.* ; Wunderlich, F.T.*

NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.

Mol. Metab. 66:101626 (2022)
Postprint Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) ranges from steatosis to nonalcoholic steatohepatitis (NASH), which often progresses to hepatocellular carcinoma (HCC) through a largely undefined mechanism. NASH and HCC depend on inflammatory signaling, whose master regulator is the NFκB transcription factor family, activated by canonical and non-canonical pathways. METHODS: Here, we investigated non-canonical NFκB-inducing kinase (NIK/MAP3K14) in metabolic NASH, NASH to HCC transition, and DEN-induced HCC. To this end, we performed dietary and chemical interventions in mice that were analyzed via single nucleus sequencing, gene expression and histochemical methods. Ultimately, we verified our mouse results in human patient samples. RESULTS: We revealed that hepatocyte-specific NIK deficiency (NIKLKO) ameliorated metabolic NASH complications and reduced hepatocarcinogenesis, independent of its role in the NFκB pathway. Instead, hepatic NIK attenuated hepatoprotective JAK2/STAT5 signaling that is a prerequisite for NASH and NASH to HCC progression in mice and humans. CONCLUSIONS: Our data suggest NIK-mediated inhibitory JAK2 phosphorylation at serine 633 that might be amenable for future therapeutic interventions in patients.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
8.568
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Nik In Nash To Hcc Progression ; Nik-mediated Jak2 Inhibition Impairs Stat5 Signaling; Nf-kappa-b; Hepatic Growth-hormone; Fatty Liver-disease; Tyrosine Kinase Jak2; Signal Transducer; Nonalcoholic Steatohepatitis; Protein-kinase; Phosphorylation; Activation; Expression
Language english
Publication Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Quellenangaben Volume: 66, Issue: , Pages: , Article Number: 101626 Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Institute of Diabetes Research and Metabolic Diseases (IDM)
POF-Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-555600-001
G-502400-001
Grants Universität zu Köln
Novo Nordisk
National Institute on Aging
National Institutes of Health
CECAD
Scopus ID 85141988963
PubMed ID 36356831
Erfassungsdatum 2022-12-06